The Cannabis Trial Did Not Test Cognition at Its First Blood-Sampling Time

forensic toxicology working group members October 31, 2026 Forensic Toxicology

The trial’s first postdose blood measurement did not have a matching cognitive-task assessment. Cognitive testing was omitted at the ten-minute time point, limiting claims about the exact alignment of the earliest concentration and performance peaks.

Measurements followed related but different schedules

After cannabis administration, the study collected blood and measured heart rate and blood pressure at approximately ten minutes and at later scheduled assessments. The investigators explicitly omitted cognitive performance tasks at ten minutes because of time limitations.

The participants were seventeen healthy adults without cannabis use in the preceding month. They completed placebo, 10 mg THC and 25 mg THC sessions using smoked and vaporized cannabis.

An observed peak depends on when measurements occur

The authors reported blood THC peaks at the first postdose sampling point and typical cognitive or psychomotor deficit peaks between thirty and sixty minutes. Those observations describe the available measurements. They cannot establish the exact cognitive performance of participants at an omitted time point.

This is especially relevant to a claim that a measured blood maximum and a maximum task deficit occurred simultaneously—or that cognition was unaffected before the first task. Neither conclusion follows from an assessment that was not performed.

Use the timeline when reviewing evidence

A clear account separates dosing time, blood collection, physiological assessment and each behavioral task. The timing gap does not erase the later measured performance effects or establish an unobserved early deficit. The pharmacokinetic companion paper comes from the same experiment, not an independent replication. The correction to the acute-effects table title also preserves the distinction between peak changes and simultaneous observations.